neurocare is revolutionizing mental
health care by providing innovative methods and tools
based on neurostimulation and other technologies to help clinicians
deliver personalized treatments with sustainable clinical outcomes
for patients. The investment will enable
the company to execute on its growth plans, including expansion
into the MENA region.
DUBAI, UAE, April 24,
2024 /PRNewswire/ -- TVM Capital Healthcare, a
specialist healthcare private equity firm headquartered in
Dubai and
Singapore, today announced a
US$ 17 million investment into
Munich-headquartered neurocare
group AG (neurocare), a leading innovator in personalized mental
health care, providing solutions to empower clinicians to deliver
best care to their patients. TVM Capital Healthcare's investment
will enable neurocare to execute on its international growth plans,
including expansion in the US and market entry into the
Kingdom of Saudi Arabia, as well
as support the development of new hardware and software
innovations. It is the ninth investment of TVM Capital Healthcare
to improve local access to quality healthcare in the MENA
region.
![TVM Capital logo TVM Capital logo](https://mma.prnewswire.com/media/2074022/TVM_Capital_Healthcare_Logo.jpg)
neurocare, through its digital therapy
platform (DTP), provides a holistic and patient centric
treatment for a variety of psychological or neurological
conditions. It uses innovative mental health care methods and tools
including sleep assessment, therapeutics, psychotherapy, TMS and
neurofeedback, all supervised within a cloud-based solution, to
empower clinicians and deliver individualized care. Following a
detailed assessment of the patient's condition, neurocare supports
clinicians in developing individualized therapy plans that are
designed to lead to strong, sustainable clinical outcomes.
neurocare's offering is used in the Company's own clinics in the
US, Europe and Australia, as well as in a growing number of
third-party clinics.
Globally, 13.0% of people are affected by mental
disorders (WHO), causing tremendous direct and indirect costs,
expected to increase from $2.5
trillion in 2010 to $6
trillion by 2030. The number of patients diagnosed with
mental illnesses doubled during the COVID pandemic. The treatment
of mental health conditions remains nevertheless significantly
lacking in most countries, leaving a considerable portion of the
population without the necessary support, and presenting a unique
growth opportunity for companies like neurocare offering innovative
non-invasive treatments with superior clinical outcomes.
Tristan de Boysson, Managing Partner, TVM
Capital Healthcare, stated: "This investment is part of our
strategy of investing in highly innovative, best-in-class
healthcare solutions that improve access to quality care across the
globe. A special objective of the Firm is improving the healthcare
infrastructure in Saudi Arabia and
the wider MENA Region. Most mental health clinics in this region
rely on traditional behavioural and drug care therapy methods, thus
creating a first mover advantage for companies like neurocare,
offering innovative mental health treatments with superior clinical
outcomes. We are excited about bringing this offering to the people
in the MENA Region and are looking forward to working together with
the neurocare management team to realize this objective."
Thomas Mechtersheimer, Founder and CEO of
neurocare group, added: "We are very pleased to announce the
cooperation with TVM Capital Healthcare, a strong partner with deep
industry experience. This partnership allows us to accelerate
neurocare's growth in our key markets in the US, Europe and Australia and expand our geographic footprint
into new regions. The implementation of our Digital Therapy
Platform into clinics in the MENA region represents a new milestone
in our company's growth. I want to thank all involved parties,
especially bm-t Thüringen, Aescuvest and Goerg Lawyers, for their
advice and support in closing this financing."
About TVM Capital Healthcare: TVM Capital
Healthcare is an emerging markets-focused healthcare private equity
firm headquartered in Dubai and Singapore, with offices in Riyadh, and Ho Chi
Minh City. The Firm invests expansion and growth capital in
healthcare companies to improve local access to quality care.
Investment and operating partners as well as a strong group of
senior advisors have long-standing international track records in
healthcare investing, active board work, contributions to strategy
development and implementation, and deep healthcare operations
experience. The Firm partners with local Middle Eastern and
Southeast Asian management teams to build domestic or regional
sector champions and selectively back companies from Europe or North
America for expansion into the Firm's two key target
geographies. TVM Capital Healthcare's investment and
operating approach combines strong commercial value creation and
returns with impact and responsible (ESG) investing.
www.tvmcapitalhealthcare.com.
About neurocare group AG: neurocare is
transforming mental health care by bringing a much-needed approach
to the field: an integrated, personalized treatment based on strong
clinical evidence. neurocare's digital therapy platform
(DTP) is the first of its kind in the area of mental
health and is empowering doctors to offer their patients the best
care for a variety of psychological or neurological
conditions. Following a detailed assessment of the patient's
condition, neurocare supports clinicians in developing
individualized therapy plans that are designed to lead to strong,
sustainable outcomes for patients, improving their self-regulation,
resilience and social skills, while being cost effective for
the healthcare system. These therapy plans integrate innovative
methods and tools, such as psychotherapy, neuromodulation and
sleep hygiene, as well as medication, to best help each
individual patient. This inclusive approach utilizing the DTP is
strongly supported by data published in leading scientific journals
which showed response rates of ~65% and >55% remission, with
very few side effects. neurocare's DTP is currently used in the
company's clinics across the US, the
Netherlands and Australia,
as well as in a growing number of third-party clinics.
www.neurocaregroup.com
Logo -
https://mma.prnewswire.com/media/2074022/TVM_Capital_Healthcare_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/tvm-capital-healthcare-announces-us-17-million-investment-into-neurocare-302124487.html
SOURCE TVM Capital Healthcare